BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), an Israel-based late clinical-stage biopharmaceutical company, announced on Tuesday that it has signed a collaboration agreement with GenFleet Therapeutics, a China-based immuno-oncology focused biopharmaceutical company.
The collaboration agreement has been signed to advance Motixafortide via a randomised Phase 2b clinical trial in pancreatic ductal adenocarcinoma (PDAC).
According to the terms of the contract, GenFleet will completely fund, design and implement a randomised Phase 2b clinical trial that will enrol around 200 first-line metastatic PDAC patients in China. The randomised controlled study is intended to assess the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. BioLineRx is to provide Motixafortide, while GenFleet will supply the other study drugs for the trial. A Joint Development Committee will administer the trial oversight. If the product is approved, GenFleet will be eligible to receive low-to-mid-single digit tiered percentage royalties on future Motixafortide sales.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study